Loading...

Champions Oncology, Inc.

CSBR•NASDAQ
Healthcare
Biotechnology
$7.37
$0.00(0.00%)

Champions Oncology, Inc. (CSBR) Stock Overview

Explore Champions Oncology, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 69.6/100

Key Financials

Market Cap99.7M
P/E Ratio16.09
EPS (TTM)$0.45
ROE6.57%
Fundamental Analysis

AI Price Forecasts

1 Week$6.19
1 Month$6.68
3 Months$9.02
1 Year Target$6.09

CSBR Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Champions Oncology, Inc. (CSBR) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $6.09.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 16.09 and a market capitalization of 99.7M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
-6.90%
↓ 6.90%
Profit Growth
$0.47
↓ 36.38%
EPS Growth
$0.47
↓ 38.46%
Operating Margin
11.48%
↓ 65.34%
ROE
656.65%
↓ 36.38%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
Buy
Hold
Sell
Strong Sell

Price Targets

Low$12.00
Average$12.00
High$12.00

Company Profile

Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company provides Lumin Bioinformatics, a software platform and data tool that contains comprehensive information derived from research services and clinical studies, and sold on an annual subscriptions basis. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.

CEO

Ronnie Morris

Employees

210

Headquarters

One University Plaza, Hackensack, NJ

Founded

2007

Frequently Asked Questions

;